

1986-2016 . 30 YEARS OF



GYNECOLOGICAL ENDOCRINOLOGY

THE 17TH WORLD CONGRESS

2-5 MARCH 2016
FIRENZE, ITALY



DEAR FRIENDS,

On behalf of the Executive Committee of the International Society of Gynecological Endocrinology (ISGE), it is my pleasure and pride to invite you to join the 17th World Congress of Gynecological Endocrinology, that as per tradition will be held in Florence on 2nd - 5th March 2016. Our biennial meeting can be considered the major event in developing, upgrading and teaching the Gynecological Endocrinology.

Gynecological Endocrinology covers all areas where hormones are active, from sub cellular effects to actions at different organs level, from reproductive tissues to the brain, from bone to heart, from sensory organs to the skin and mucosa. The impact on metabolism, aging processes, tissue regeneration and stem cells, are important chapters of interest for our Society.

The Scientific programme, developed by the Executive Board, will receive contributions from Scientific Societies, mostly members

of the International Federation of the Societies of Gynecological Endocrinology (FISGE), that cooperates with us.

Moreover, the Congress' Scientific Programme welcomes suggestions of our Members, Working groups and any other Institution that want to increase both the scientific and the educational level of the Event.

The ISGE 2016 World Congress will be preceded by the International School of Gynecological and Reproductive Endocrinology (ISGRE) winter and summer Teaching Courses, which respectively will be held in Madonna di Campiglio by the end of January 2015 and in late June 2015 in Montpellier. Visit www.isgesociety.com for more information.

I strongly hope to receive your proposals for the progress of our Society, and have the pleasure to meet you in Florence in March 2016.

Andrea R. Genazzani
(President of ISGE)



THE INTERNATIONAL SOCIETY OF GYNECOLOGICAL ENDOCRINOLOGY is a non-profit organisation established in 1986 for the purpose of promoting science and research into all aspects of Gynecological Endocrinology and communication between scientists interested in these subjects.

The Society operates through

- o the monthly Journal of Gynecological Endocrinology,
- o the FISGE (International Federation of the Societies of Gynecological Endocrinology)
- o the ISGRE (International School of Gynecological and Reproductive Endocrinology)
- o the biannual World Congress of Gynecological Endocrinology, a major scientific event which allows a perfect integration of renowned faculty members with talented young scientists presenting innovative research.

GET INVOLVED: BECOME A MEMBER

If you are interested in our activities consider to become an ISGE member: you will receive news on all our events and you will have access to the Members area of the ISGE website with:

- o **Free Access** to the digital edition of the Gynecological Endocrinology Journal;
- o **abstracts and lectures** from the latest Isge World Congresses;
- o **free extra contents** from past ISGRE Courses;
- o **discounts** on ISGRE courses and ISGE congresses.

Please visit the society website www.gynecologicalendocrinology.org to register.

BOARD 2014-2018

PRESIDENT

Genazzani Andrea R.(IT)

TREASURER

Birkhaeuser Martin (CH)

EXECUTIVE SECRETARY

Simoncini Tommaso (IT)

BOARD MEMBERS

Adamyani Leila (RU)

Berga Sarah (US)

Bouchard Philippe (FR)

Brincat Mark (MT)

Chedraui Peter (EC)

De Melo Nilson (BR)

Devoto Luigi (CL)

Fauser Bart C. (NL)

Foidart Jean Michel (BE)

Linden Hirschberg Angelica (SE)

Maruo Takeshi (JP)

Milewicz Andrzej (PL)

Naftolin Frederick (US)

Nappi Rossella E. (IT)

Ruan Xiangyan (CN)

Schindler Adolf (DE)

Simon Carlos (ES)

Siseles Nestor (AR)

Sitruk-Ware Regine (US)

Stevenson John C (UK)

Sultan Charles J. (FR)

Tarlatzis Basil (GR)

SCIENTIFIC PROGRAM

The Congress will be organized in

- Plenary Lectures
- Debates
- Meet the Expert
- Plenary Sessions
- Lunch Symposia

Each session will include three or four speakers each presenting his scientific research in approximately 20 minutes plus 5 minutes discussion.

Moreover will be available:

- Oral Presentations
- Poster Session

Opening lectures

Lunenfeld Bruno (IL) The role of KIS peptides in the regulation of the ovulatory cycle

Pecorelli Sergio (IT) The evolution of medicine: innovation, new drugs, economic

Plenary Lectures

Braennstroem Mats (SW) Human uterus transplantation with live births

Santen Richard (US) Personalized medicine for menopause: where are we in 2016?

Sultan Charles J. (FR) Anorexia nervosa: new developments in endocrinology and metabolism

Bouchard Philippe (FR) From cortisol to estradiol and progesterone: can we effectively manipulate tissue content of steroids?

	AUDITORIUM 1000 PAX		VERDE 190 PAX		POSTER AREA
Wednesday, March 2nd					
10.00-13.00	Special session for Under 34 Award & Residents		Precongress Course		
14.30-15.30	ISGE Award winners				
15.40-17.10	Opening Symposium				
17.20-18.00	Opening Ceremony				
18.00-18.30	Opening Lecture				
18.30-19.00	Opening Lecture				
19.00-21.00					Poster Session and welcome reception
	AUDITORIUM 1000 PAX	AFFARI 1 400PAX	AFFARI2 250PAX	VERDE 190 PAX	ONICE 70 PAX
Thursday, March 3rd					
08.30-09.30	Session by Sci. Soc.	Session by Sci. Soc.	Session by Sci. Soc.	Session by Sci. Soc.	Session by Sci. Soc.
09.45-11.15	Plenary Session	Plenary Session	Plenary Session	Plenary Session	Oral Presentation
11.15-11.45	Visit to the Exhibition Area				
11.45-13.15	Plenary Session	Plenary Session	Plenary Session	Plenary Session	Oral Presentation
13.45-15.15		Lunch Symposium	Lunch Symposium		
15.15-15.45	Visit to the Exhibition Area				
15.45-16.45	Meet the expert	Meet the expert	Meet the expert	Meet the expert	Oral Presentation
16.45-18.15	Plenary Session	Plenary Session	Plenary Session	Plenary Session	Oral Presentation
18.15-19.15		ISGE Assembly			
Friday, March 4th					
08.30-09.30	Session by Sci. Soc.	Session by Sci. Soc.	Session by Sci. Soc.	Session by Sci. Soc.	Session by Sci. Soc.
09.45-11.15	Plenary Session	Plenary Session	Plenary Session	Plenary Session	Oral Presentation
11.15-11.45	Visit to the Exhibition Area				
11.45-13.15	Plenary Session	Plenary Session	Plenary Session	Plenary Session	Oral Presentation
13.45-15.15		Lunch Symposium	Lunch Symposium		
15.15-15.45	Visit to the Exhibition Area				
15.45-16.15	Plenary Lecture	Plenary Lecture	Plenary Lecture	Plenary Lecture	
16.30-18.00	Plenary Session	Plenary Session	Plenary Session	Plenary Session	Oral Presentation
18.00-19.30		Plenary Session	Plenary Session	Plenary Session	Oral Presentation
Saturday, March 5th					
08.30-10.00		Plenary Session		Plenary Session	Oral Presentation
10.15-11.15		Meet the expert		Meet the expert	Oral Presentation
11.15-11.45	Break				
11.45-13.15		Plenary Session		Plenary Session	Oral Presentation
13.15-13.45		Closing Assembly			

SCIENTIFIC PROGRAM

Plenary Sessions

① New insight into female- specific factor that influence brain function

Maki Pauline (US) The link between vasomotor symptoms and memory decline: how strong is the evidence?

Schagen Sanne (NL) Cognition and brain function and structure in breast cancer survivors: effects of systemic therapy

Hunter Myra (UK) Cognitive Behavior Therapy as a treatment for VMS: Evidence from RCTs and mechanism of action

Matsumoto Tamaki (JP) The central autonomic network and premenstrual disorders

② Neuroendocrinology from basic science to clinical impact

Naftolin Frederick (US) Creating positive feedback in organ culture of the rat hypothalamus

Bouchard Philippe (FR) Hypogonadotropic hypogonadisms etiologies and applications

Berga Sarah (US) The neuroendocrine impact of cognitive behavior therapy of stress-induced anovulation

Maki Pauline (US) Stress responsivity in midlife women: the role of childhood trauma

③ Breast cancer risk and hormones - part 1

Kiesel Ludwig (DE) Progestins and breast carcinogenesis

Ruan Xiangyan (CN) Dependency on dosage, duration, regimen and type?

Biglia Nicoletta (IT) Risk of breast cancer following fertility treatments

Santen Richard (US) Can therapies for menopausal symptoms prevent breast cancer at the same time?

④ Breast cancer risk and hormones - part 2

Mueck Alfred (DE) Preconditions of genotoxic estrogen metabolites to induce breast cancer

Sismondi Piero (IT) Obesity, inflammation and breast cancer

Von Schoultz Bo (SW) Are androgens risk factors or protective for the breast?

Foidart Jean Michel (BE) Endocrine sensitivity of normal and malignant breast: a concern?

⑤ Metabolic Syndrome

Berga Sarah (US) Stress, emotional eating, and reproduction: role of GABA

Genazzani Alessandro D. (IT) Insulin resistance, PCOS and obesity: integrative treatments that can improve insulin sensitivity

Chedraui Peter (EC) The metabolic syndrome after the menopause: pro-inflammation and endothelial dysfunction

Perez-Lopez Faustino (ES) Insulin resistance and endometrial cancer

⑥ Sport and female reproductive function

Paoletti Annamaria (IT) Thinness and physical activity

Sultan Charles J. (FR) Female athletes and bone mass acquisition: a paradox?

Hirschberg Angelica L. (SW) Hyperandrogenism and PCOS in female athletes: an advantage for physical performance?

Lachowsky Michèle (FR) Physical activity today: a new period for periods

⑦ PCOS

Milewicz Andrzej (PL) Serum Glipikan 4 levels in women with PCOS

Fauser Bart C. (NL) PCOS: reproductive dysfunction and long-term cardiovascular health implications

Tarlatzis Basil (GR) Can we eliminate OHSS in PCOS women undergoing ovarian stimulation for IVF?

Perez-Lopez Faustino (ES) Obesity and metabolic syndrome in adolescents

⑧ Sexuality

Castelo Branco Camil (ES) Sexuality and quality of life in congenital hypogonadisms

Hirschberg Angelica L. (SW) Influence of oral contraceptives on sexuality: evidence from randomized placebo-controlled trials

Bitzer Johannes (CH) Sexual pain: how to manage?

Nappi Rossella E. (IT) Is a sexy life an healthy life at menopause?

⑨ Pregnancy and progesterone

Devoto Luigi (CL) Progesterone from Ovulation to Pregnancy

Petraglia Felice (IT) Pregnancy at risk in women with reproductive disorders

Schindler Adolf (DE) Type of progestogen used for treatment and prevention of pregnancy disorders and mechanisms of action

Carp Howard (IL) Results of recent meta analyses on progestogens in threatened and recurrent miscarriage

⑩ HRT and cardiovascular risk

Lambrinoudaki Irene (GR) Managing cardiometabolic risk after menopause

Collins Peter (UK) Management of coronary disease in post-menopausal women

Siseles Nestor (AR) Cardiovascular health in menopausal woman when to begin the hormone treatment?

Birkhaeuser Martin (CH) Why prefer transdermal to oral Menopausal Hormone Therapy



11 Neurosteroids the brain as a target

Sitruk-Ware Regine (US) Progesterone and the brain

Schumacher Michael (FR) Androgen and the brain

Genazzani Andrea R. (IT) Estrogens and the brain

Brinton Diaz Roberta (US) Allopregnanolone as a regenerative therapeutic for Alzheimer's Disease

12 Atherosclerosis in women

Stevenson John C. (UK) Assessment of cardiovascular risk at the menopause

Arnal Jean-Francois (FR) Understanding the tissue specific action of estrogens and selective estrogen receptor modulators

Simoncini Tommaso (IT) Role of progesterone and progestins on endothelial coagulation and fibrinolytic pathways

13 IVF from the patients to the clinic

Artini Paolo G. (IT) Gene expression in cumulus cells and IVF outcome

Gianaroli Luca (IT) NGP: new generation patients

Barri Pedro (ES) PGS in IVF implantation failure

Donnez Jacques (BE) Should we treat myomas before IVF? If yes, which treatment?

14 IVF: the therapies

La marca Antonio (IT) How to choose the FSH starting dose in IVF

Imthurn Bruno (CH) Clinical and patient experience with a novel r-hFSH in IVF

Shoham Zeev (IL) How aggressive we need to be with luteal phase support? Progesterone, Estrogen, GnRH agonist, or hCG

Lunenfeld Bruno (IL) Towards a hyperstimulation free clinic

15 Vitamin D and bone metabolism

Milewicz Andrzej (PL) Vitamine D Binding Proteine and VDR gene polymorphisms in women PCOS

Brincat Mark (MT) A new look at Vitamin D and its Pharmacological application in Infertility

Al-Azzawi Farook (UK) The clinical choice between oestrogen and bisphosphonates in the prevention of post-menopausal osteoporosis - are women being misled?

Palacios Santiago (ES) New strategies in the treatment of osteoporosis

16 Reconstructive surgery

Creatsas George (GR) Vulvovaginal congenital anomalies

Fedele Luigi (IT) Creation of a neovagina by Davydov's laparoscopic modified technique in patients with Rokitansky syndrome

Adamyan Leila (RU) Updated strategy for myoma, endometriosis and adenomyosis

Mettler Liselotte (DE) When is tubectomy and when ovariectomy indicated in benign gynecological surgery

17 High risk pregnancy

Holzgreve Wolfgang (DE) Non-invasive prenatal diagnostics from material blood - finally available in clinical practice.

Hod Moshe (IL) Towards a universal consensus on diagnosis of GDM - The FIGO GDM initiative project

Ferrazzi Enrico (IT) Clinical phenotypes of pre-eclampsia

Di Renzo Giancarlo (IT) Prevention and management for postpartum hemorrhage in anomalies of placenta insertion

18 Ovarian cancer and androgens secreting tumors

Kenemans Peter (NL) Ovarian carcinoma in BRCA mutation carriers

Benedetti Panici Pier Luigi (IT) Conservative Surgery for the Treatment for Epitelial Ovarian Cancer

Gadducci Angiolo (IT) Parp inhibitors in ovarian cancer

Noelting Manuel (AR) Androgens secreting tumors

19 DUB and fibroids

Goldstein Steven R. (US) Diagnosis of DUB: the standard of care has changed!

Lumsden Mary Ann (UK) Studies of the mechanism of action of UAE

Maruo Takeshi (JP) Lessons learned from the preclinical studies with PRMs for non-surgical treatment of uterine fibroids

Sciarra John J. (US) New Management for Uterine Fibroids

20 Clinical trials in menopause

Naftolin Frederick (US) An update of studies on HRT since the WHI

Shierbeck Louise (DK) Cardiovascular disease in postmenopausal women; does HRT have a role?

Canonico Marianne (FR) HRT and venous thromboembolism... what differences between US and South European treatments?

Pickar James (US) The rejoice trial for Dyspareunia: a new solubilized estradiol (VagiCap™), implications for labeling

21 Menopause and personal risks

Cano Antonio (ES) Personalized medicine after menopause: the case of women with profiles of risk

De Geyter Christian (CH) Effects of HRT on gene expression in breast tissue of healthy post-menopausal women.

Brincat Mark (MT) Muscolo skeletal changes in the menopause and their response to HRT

Studd John (GB) Hormone therapy for depression and loss of libido

22 Hypogonadism and POF

Panay Nick (UK) POI Registry: New frontiers in global collaboration

Ben Rafael Zion (IL) Poor ovarian reserve- what can be done?

Meczekalski Blazej (PL) Long-term consequences of POF

Vujovic Svetlana (SR) Factors improving fertility rate in premature ovarian failure



SCIENTIFIC PROGRAM

23 Contraception from needs to possibilities

De Melo Nilson R. (BR) Contraception in special situations

Schindler Adolf (DE) Progestogen-only contraceptives: benefits and risks

Sitruk-Ware Regine (US) Progesterone receptor modulators for contraception

Nappi Rossella E. (IT) Pain threshold modulation by CHC in women with menstrual-related migraine

24 Fertility preservation

Fauser Bart C. (NL) Fertility preservation: How to balance potential benefits versus risks

Anderson Richard A. (UK) Personalizing decision making in fertility preservation

Donnez Jacques (BE) Restoration of ovarian activity and fertility after ovarian tissue transplantation

Benedetto Chiara (IT) Pregnancy outcomes after autologous transplantation

Meet the expert

Endometrium

Simon Carlos (ES) Scratch or not to Scratch?

Goldstein Steven R. (US) Modern evaluation of the endometrium

Endometriosis

Petraglia Felice (IT) Mechanisms of action of medical treatments

Kiesel Ludwig (DE) When and how to treat deep-infiltrating endometriosis prior to IVF

Stem cells from the therapy to the practice

Simon Carlos (ES) Stem Cell Therapy of the Endometrium in Asherman's syndrome and atrophic endometrium

Anderson Richard A. (UK) Ovarian Germline stem cells

From vulvo vaginal atrophy to genito-urinary syndrome of menopause

Nappi Rossella E. (IT) The biopsychosocial model is needed to understand the reality of FSD

Shifren Jan L. (US) From vulvovaginal atrophy to the genitourinary syndrome of menopause: what's in a name?

25 Women beyond menopause: problems, objectives, hopes and our responsibilities

Rees Margaret (GB) Empowering healthy ageing in women

De Villiers Tobias (ZA) MHT 2016: do the experts agree?

Gompel Anne (FR) Progestins and breast cancer Risk highlights from France?

Schenker Joseph G (IL) Aging and Reproduction – Medical Aspects

26 Stress, Pregnancy and Stem Cells

Taylor Robert (US) Stress, Telomeres, and Preterm Labor

Whirledge Shannon (US) Stress-induced Infertility: the Impact of Glucocorticoids on Endometrium and Implantation

Gammill Hilary (US) Maternal Consequences and Microchimerism (stem cells of fetal origin)

Scientific Societies Symposia

Additional symposia will be organized by the following

Scientific Societies

- Endocrine Society
- Asociación Latinoamericana de Endocrinología Gin. (ALEG)
- European Soc. of Contraception and Reproductive Health (ESC)
- European Society of Gynecology (ESG)
- Federación Latina de Endocrinología Ginecológica (FLEG)
- Hungarian Society of Gynecological Endocrinology
- International Academy of Human Reproduction (IAHR)
- International Consortium for Male Contraception (ICMC)
- International Menopause Society (IMS)
- Mediterranean Society of Reproductive Medicine (MSRM)
- Polish Society of Gynecological Endocrinology



REGISTRATION FEES

Registration fees	Until 26/10/2015	Until 18/01/2016	After 18/01/2016	On site
Delegate	€ 500,00	€ 650,00	€ 750,00	€ 850,00
Delegate from Developing Countries (WHO list)	€ 400,00	€ 550,00	€ 650,00	€ 750,00
Residents, nurses and technicians (official certificate required)		€ 200,00	€ 300,00	€ 400,00
Isge Member	€ 400,00	€ 550,00	€ 650,00	€ 750,00
Isge Member from Developing Countries (WHO list)	€ 350,00	€ 500,00	€ 600,00	€ 700,00
Isge Member - residents, nurses and technicians* (official certificate required)		€ 150,00	€ 250,00	€ 350,00
Participant to the Under 34 Competition	€ 150,00	€ 150,00	must register before	

REGISTER NOW!

Fill out the registration form on www.isgesociety.com/isge2016

Payment accepted with all the major credit cards or bank wire.

1. Create for free an account on the website;
2. Complete the registration to the congress;
3. With your account you can also send an abstract, book a hotel or print your invitation letter.

Registration Fee includes:

- Opening Ceremony
- Closing Ceremony
- Access to all sessions
- Access to exhibition area
- Congress kit
- Abstract Book/CD
- CME credits
- Two years ISGE Subscription including the access to the PDF version of the Gynecological Endocrinology Journal

Cancellation policy for registration

Refunds (less € 25,00 for taxes and administrative expenses) will be granted to delegates unable to attend. A written notice must be received by the Organizing Secretariat before January 18th, 2016. No refunds will be made for cancellations received after January 18th, 2016. All refunds will be issued after the Congress.

Group registration

If you are interested in a group registration (10 persons or more), please email the Congress Secretariat at isge2016@btcongress.com for further information. Please note that no registration will be made without full personal contact details for each participant. Blank registrations are not allowed.

Insurance The Congress Organizers will not accept any liability for personal injury, or loss/damage to property or belongings of participants, either during or as a result of the Congress during their stay in Berlin. It is, therefore, recommended that participants arrange their own personal health, accident and travel insurance.

SECRETARIATS

Organizing Secretariat

[Biomedical Technologies srl](http://www.btcongress.com)
www.btcongress.com
 T. 070340293
isge2016@btcongress.com

Scientific Secretariat

Chairman of the Congress
 A.R.Genazzani (IT)
isge@tiscali.it



◀ David by Michelangelo
 Galleria dell'Accademia (Firenze)

Present your paper at the most important congress
in Gynecological Endocrinology:

CALL FOR ABSTRACTS

Send your abstract, you have time until November 30.

Rules for Abstract submission

- Deadline for abstract submission: **November 30th 2015**;
- Each person is allowed to submit a maximum of two abstracts as presenting author: one oral presentation and one poster or, alternatively, two posters. There is no limit to the number of abstracts submitted as co-author;
- Presenting authors will be notified whether their abstracts are accepted by December 23rd 2015. Further details on the schedule and instructions for oral and poster presentations will be available online.
- Authors whose abstracts have been accepted must register for the Congress and pay the registration fee by January 18th 2016. Failure to do so, will result in exclusion from the programme and the Book of Abstracts;
- The Scientific Programme of the Congress will be available online on February 2015;
- Abstracts can only be submitted using the on-line form. Abstracts submitted via email or fax will not be accepted.

To submit an abstract

1. Visit www.isgesociety.com/isge2016
2. Create your free account on the website
3. Once logged in to your account, click on the Abstract Submission link

Main topics for abstract submission

The topic of your abstract is not in this list? Check the complete list online!

1. GYNECOLOGICAL ENDOCRINOLOGY
2. CONTRACEPTION
3. MEDICALLY ASSISTED PROCREATION
4. OBSTETRICS
5. GYNECOLOGY
6. MENOPAUSE AND AGEING
7. GYNECOLOGICAL ONCOLOGY
8. THE BREAST
9. GYNECOLOGICAL SURGERY
10. DIAGNOSIS



The Congress is supported by



GEDEON RICHTER

